Used at the point of care, the LumiraDx SARS-CoV-2 Ag Test verifies COVID-19 infection in minutes so that a patient can rapidly begin treatment and take precautions to prevent the spread of infection. The tests are run on a proprietary platform that uses an actively controlled microfluidic technology, helping to provide fast, accurate, comprehensive diagnostic data. LumiraDx’s portable and lab-comparable point of care diagnostic platform supports a broad menu of tests, with 30 either on the market or in development, covering infectious diseases, cardiovascular diseases, diabetes, and coagulation disorders.

• LumiraDx
  For more information, visit medlabmag.com/info